summary Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components. Although many of therapies have shown great e‹cacy, they often associate with adverse eŠects. The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the in‰ammatory process in SLE. The cytokine family of type I interferons (IFNs), and especially the IFNa subtypes, are implicated in pathogenesis of SLE. Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE. Therefore, IFNa subtypes have been identiˆed as a potential target for drug development in SLE. There have been developed three agents, IFNa-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152 0000 0001. They are anti-IFNa monoclonal antibodies that bind to and speciˆcally neutralizes most IFNa subtypes, preventing signaling through the type I IFN receptor. The safety and dose-proportional pharmacokinetics of those agents were demonstrated. A larger study is currently ongoing, further safety proˆle will be evaluated. This review provides an update on the ongoing clinical trials of anti-IFNa therapy and the promise and obstacles in the use of biologics in SLE. 
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